Company intelligence / Profile preview

Harmony Biosciences

Plymouth Meeting, Pennsylvania, United States

Ownership: Public · HRMY
Development stage: Other

Overview

Harmony Biosciences is commercial-stage with its lead product WAKIX (pitolisant) FDA-approved for excessive daytime sleepiness or cataplexy in adult narcolepsy; it is also advancing clinical-stage programs for additional rare neurological disorders such as Fragile X syndrome and investigational assets in narcolepsy.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Bioprojet (exclusive US license for pitolisant)ConSynance Therapeutics (HBS-102 asset acquisition)

Beyond the preview

Go deeper on Harmony Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harmony Biosciences.

Explore the full profile